PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26244344-4 2015 In the present work, using docking and molecular dynamics methodologies, we established the most probable binding sites of SB-206553, a drug originally described as a competitive antagonist of serotonin type 2B/2C metabotropic receptors (5-HT2B/2CRs) and more recently as a positive allosteric modulator of the ionotropic alpha7 nicotinic acetylcholine receptor (nAChR). SB 206553 123-132 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 363-368